Conference
The Canadian Cancer Trials Group PA.7 trial: Results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)
Authors
Renouf DJ; Knox JJ; Kavan P; Jonker D; Welch S; Couture F; Lemay F; Tehfe M; Harb M; Aucoin N
Volume
31
Publisher
Elsevier
Publication Date
September 1, 2020
DOI
10.1016/j.annonc.2020.08.2300
Conference proceedings
Annals of Oncology
ISSN
0923-7534